eBioscience acquires Bender MedSystems' immunoassay technology
29 October 2009
eBioscience Corporation has acquired privately held Austrian
immunoassay technology pioneer Bender MedSystems GmbH in an all cash
The acquisition will provide eBioscience with over 1,000 high profile
immunology and oncology products, including the Instant ELISA and
FlowCytomix brands that target the life sciences and diagnostics
"Bender MedSystems provides us with a cutting-edge technology
platform that, when combined with many of eBioscience's leading cell
analysis research and diagnostic products, will facilitate the
accelerated development and commercialization of breakthrough
innovations," explained eBioscience CEO, Todd R. Nelson Ph.D.
"Bender MedSystems proprietary Instant ELISA technology and
associated product lines confer several major competitive advantages
over existing technologies including increased sensitivity,
significantly simplified handling and reduced analysis time," added
Michael Schaude Ph.D., CEO of Bender MedSystems.
Bender MedSystems' novel bead based multiplexing technology and
products, marketed and sold under the FlowCytomix brand, allow
researchers to analyze simultaneously up to 20 proteins in a single
reaction. This highly scalable technology platform can be combined with
many of eBioscience's existing technologies that the company intends to
use in the development of a significant number of expanded sets of cell
analysis product lines.
"The FlowCytomix reagents are designed to run on existing flow
cytometry instruments, allowing eBioscience to take full advantage of
our current commercial channel without having to invest into an
instrument platform. Accordingly, the technology represents an
exceptional opportunity for us to increase our presence within the
multiplexing segment of the immunoassay market," Dr. Nelson commented.
The Bender MedSystems' acquisition builds on eBioscience's recent
expansion in Europe and is complementary to the company's NatuTec
operations in Germany. In addition to providing eBioscience with a first
class centre of excellence for the development of immunoassays in
Europe, the company will now have manufacturing, enhanced customer
service, technical support and increased regional distribution
Bender MedSystems will serve as eBioscience's European headquarters
and will greatly enhance the ability to get products to customers more
rapidly and reliably," added Dr. Nelson.
"Bender MedSystems has built an impressive business over the past 11
years and has amassed a quality brand, several highly scalable enabling
technologies and value-added product lines and it will be a pleasure to
add them to the eBioscience family of companies," Nelson commented.